Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tango Therapeutics, Inc. on January 5, 2026, covering events occurring on January 2, 2026. The Company is a Delaware corporation with its principal executive offices in Boston, MA, and its common stock trades on The Nasdaq Global Market under the symbol TNGX. The filing reports the appointment of a new director and the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.
Material Changes
On January 2, 2026, the Board of Directors increased the number of directors from seven to eight. Sung H. Lee was appointed to fill the newly created vacancy. Mr. Lee is considered independent under Nasdaq listing standards and will serve as a Class I director until the 2028 annual meeting of stockholders.
Compensation and Governance Details
- Equity Awards: Mr. Lee received a stock option to purchase 60,000 shares at an exercise price of $8.93 per share and a restricted stock unit (RSU) award for 10,000 shares.
- Vesting Schedule: The stock option vests in 36 equal monthly installments over three years. The RSU award vests in three equal annual installments over three years. Vesting for both awards ceases if Mr. Lee stops serving on the Board.
- Cash Compensation: Mr. Lee will receive an annual retainer of $40,000.
- Committee Assignments: Mr. Lee has not been named to any Board committee at this time.
- Indemnification: The Company expects to enter into a standard indemnification agreement with Mr. Lee.
Outlook and Risks
The filing does not contain management commentary on business outlook, risks, contingencies, or unusual items. The Company issued a press release on January 5, 2026, announcing the appointment, which is incorporated by reference as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the independence status of Sung H. Lee under Nasdaq listing standards.
- Confirm the total number of directors is now eight.
- Review the specific terms of the stock option (60,000 shares at $8.93) and RSU (10,000 shares) grants.
- Check for any future committee assignments for the new director.
- Confirm the execution of the indemnification agreement referenced in the filing.